Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Wisconsin, Madison |
---|---|
Information provided by: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00205257 |
Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.
Condition | Intervention | Phase |
---|---|---|
Kidney Transplant |
Device: Urine Chemokine Test |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2001-252 |
Study First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00205257 |
Health Authority: | United States: Food and Drug Administration |